Along with the FDA-approved CDK4/6 inhibitors, other CDK4/6 inhibitors (i.e., dalpiciclib, lerociclib, SPH4336, TQB3616, TQB3303, XZP-3287, HS-10342, PRT3645, FCN-437c, BPI-1178, GLR2007, and CS3002) have been tested in a variety of malignancies. Here, CDK4 is linked to cancer.